In Early 2020, just as the covid-19 pandemic was starting to unfold, infectious disease researchers Matt Memoli and Luca Giurgea were already thinking about how the crisis might end. The two, both at the Laboratory of Infectious Diseases at the National Institutes of Health, recalled what happened following a coronavirus epidemic 17 years earlier, and they were concerned about a repeat.
They remembered that, as sars (caused by a kind of coronavirus) jumped to humans, possibly from bats, and began spreading across the globe in late 2002— eventually infecting more than 8,000 people and killing 774—researchers started working on some of the first commercial human coronavirus vaccines. But within months, health authorities contained the outbreak. And as the threat of sars subsided, so did their funding. Projects were put on hold or abandoned.
Too bad, because they really could have come in handy.
Continue reading your story on the app
Continue reading your story in the magazine
Private equity's favorite tax break is one of Washington's favorite punching bags. So why can't anyone get rid of it?
A Few Good Men
Valley Forge Military Academy bills itself as a school that breaks down young cadets and builds them back better. It succeeds at one of those things.
DANCE DANCE REVOLUTION
Calvin Royal III wants to help "break ballet out of the 18th century."
Can local food delivery co-ops take on the Big Tech apps?
How the scientific label has masked political choices
LESSONS NOT LEARNED
How the Oxford school massacre could have been stopped
Real estate investors had a great plan to cash in on pandemic-era Brooklyn. But tenants are fighting back.
No Quick Fix
Two national companies took over the motorized wheelchair industry. Disabled customers have been paying the price.
How a group of Coloradans fought like hell to wrest their "poor people's paradise" from the grip of a PE-backed firm
How to cash in on federal climate tax credits...by shuttling ethanol emissions across five states.